Welcome to our dedicated page for Concentrix SEC filings (Ticker: CNXC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Concentrix Corporation (NASDAQ: CNXC) SEC filings page on Stock Titan provides access to the company’s official disclosures as filed with the U.S. Securities and Exchange Commission. As a Fortune 500 public company, Concentrix uses SEC reports to communicate details about its financial performance, risk factors, capital structure, and significant corporate events.
Among the key filings, investors typically review annual reports on Form 10-K and quarterly reports on Form 10-Q to understand revenue trends, operating income, non-GAAP measures referenced in earnings releases, cash flow, and segment information. Current reports on Form 8-K, such as those furnished for quarterly earnings announcements, give timely updates on results of operations and financial condition, and may include press releases as exhibits.
For those tracking ownership and governance, Forms 3, 4, and 5 (if available) can be used to monitor insider transactions by directors, officers, and significant shareholders. Proxy statements on Schedule 14A, when filed, typically provide information on executive compensation, board structure, and matters submitted to shareholder votes.
On Stock Titan, Concentrix filings are supplemented with AI-powered summaries that explain the main points of lengthy documents in clear language. Real-time updates from the EDGAR system help users see new CNXC filings as they appear, while AI-generated highlights make it easier to identify sections related to non-GAAP metrics, AI and technology investments, and other topics emphasized in the company’s earnings materials. This page is a useful starting point for anyone researching Concentrix’s regulatory history, financial reporting practices, and material disclosures.
Concentrix Corporation reported modest revenue growth but sharply lower profit for the quarter ended February 28, 2026. Revenue rose 5.4% to $2,500,391 thousand, driven by strength in retail, travel and e-commerce, banking, and communications, partly offset by softer technology and healthcare demand.
Operating income fell to $118,559 thousand from $168,867 thousand, and net income dropped to $21,589 thousand, or $0.33 per diluted share, versus $1.04 a year earlier, as gross margin compressed to 34.0% and restructuring, integration, and a $5,929 thousand loss on a non-core business held for sale weighed on results.
Operating cash flow swung to an outflow of $83,220 thousand, reflecting working capital movements. Long-term debt remained high at $4,011,750 thousand before discounts, including new $600,000 thousand 6.500% 2029 Senior Notes used to redeem an equal amount of 2026 Notes. The company repurchased $43,194 thousand of stock and paid a quarterly dividend of $0.36 per share.
Concentrix Corp President and CEO Christopher A. Caldwell reported an open-market purchase of company stock. On March 26, 2026, he bought 1,000 shares of Concentrix common stock at an average price of $26.97 per share. Following this transaction, he directly owns 357,382 shares of Concentrix common stock.
Concentrix Corp director LaVerne H. Council received an equity award of 7,701 shares of Common Stock in the form of restricted stock units. These RSUs were granted at no cash exercise price and increase her direct holdings to 17,704 shares following the award. The units vest in full on the earlier of the one-year anniversary of the grant date or the company’s 2027 Annual Meeting of Stockholders, aligning director compensation with long-term shareholder interests.
Cheng Chih-Kai reported acquisition or exercise transactions in this Form 4 filing.
Concentrix Corp director Cheng Chih-Kai received a grant of 7,701 shares of Common Stock as restricted stock units. These RSUs were awarded at no cash purchase price under the company’s 2020 Stock Incentive Plan and represent his entire reported direct holding after the transaction.
The restricted stock units will vest in full on the earlier of the one-year anniversary of the grant date or the date of Concentrix Corp’s 2027 Annual Meeting of Stockholders. This filing reflects a compensation-related equity award rather than an open-market share purchase or sale.
OGUT BILGE reported acquisition or exercise transactions in this Form 4 filing.
Concentrix Corp director Bilge Ogut received 7,701 shares of common stock as a restricted stock unit award. The grant was made at no cash cost to the director and represents equity-based compensation rather than an open-market purchase or sale.
According to the terms, these restricted stock units vest in full on the earlier of the one-year anniversary of the grant date or the date of Concentrix’s 2027 Annual Meeting of Stockholders. After this award, Ogut holds 7,701 shares directly, aligning personal ownership with shareholder interests through time-based vesting.
Deason Jennifer reported acquisition or exercise transactions in this Form 4 filing.
Concentrix Corp director Jennifer Deason received an equity award rather than buying shares on the market. She was granted 7,701 shares of common stock in the form of restricted stock units at no cash purchase price, increasing her direct holdings to 17,704 shares.
The restricted stock units were awarded under the 2020 Stock Incentive Plan and will vest in full on the earlier of the one-year anniversary of the grant date or the date of Concentrix’s 2027 Annual Meeting of Stockholders. This is a compensation-related grant, not an open-market transaction.
Hayley Kathryn reported acquisition or exercise transactions in this Form 4 filing.
Concentrix Corp director Hayley Kathryn received an equity award of 7,701 shares of Common Stock as restricted stock units under the 2020 Stock Incentive Plan. The units were granted at no cash cost and will vest in full on the earlier of the one-year anniversary of grant or the company’s 2027 Annual Meeting of Stockholders.
After this award, Kathryn directly holds 17,712.1206 shares. She also has an indirect holding of 3,034.2930 shares held by a trust, giving her both direct and trust-based exposure to Concentrix stock.
Marinello Kathryn V reported acquisition or exercise transactions in this Form 4 filing.
Concentrix Corp director Kathryn V. Marinello received an equity grant of 7,701 shares of common stock as restricted stock units. The award was made at no cash price under the 2020 Stock Incentive Plan and vests in full on the earlier of the one-year anniversary of the grant date or the issuer's 2027 Annual Meeting of Stockholders. Following this grant, she directly holds 17,704 shares of Concentrix common stock.
POLK DENNIS reported acquisition or exercise transactions in this Form 4 filing.
Concentrix Corp director Dennis Polk received an equity award of 7,701 shares of Common Stock in the form of restricted stock units. The grant was made at no cash cost per share and increased his direct holdings to 28,924 shares. These restricted stock units, awarded under the 2020 Stock Incentive Plan, vest in full on the earlier of the one-year anniversary of the grant date or the date of Concentrix’s 2027 Annual Meeting of Stockholders.
VEZINA ANN F reported acquisition or exercise transactions in this Form 4 filing.
Concentrix Corp director Ann F. Vezina received a grant of 7,701 shares of Common Stock in the form of restricted stock units. The award was made at no cash price and increases her direct holdings to 19,648 shares.
The restricted stock units were granted under the 2020 Stock Incentive Plan and will vest in full on the earlier of the one-year anniversary of the grant date or the date of Concentrix’s 2027 Annual Meeting of Stockholders.